Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GentiBio raises $157m through Series A funding round
Biotherapeutics company GentiBio has raised $157m through a Series A funding round, which was led by Matrix Capital Management. The firm plans to use the proceeds from the
Biotherapeutics company GentiBio has raised $157m through a Series A funding round, which was led by Matrix Capital Management. The firm plans to use the proceeds from the
The US Food and Drug Administration (FDA) has declined to approve AstraZeneca and FibroGen’s new drug application (NDA) for roxadustat to treat anaemia associated with chronic kidney disease
The US Food and Drug Administration (FDA) has granted priority review for Merck’s supplemental biologics license application (sBLA) for KEYTRUDA (pembrolizumab) as adjuvant therapy for patients with renal
Biotechnology firm Moderna and Canadian government have signed a memorandum of understanding (MoU) to construct a new messenger RNA (mRNA) vaccine manufacturing facility in Canada. The latest deal
INO-4800 features a particularly designed deoxyribonucleic acid (DNA) plasmid. To be injected intradermally with subsequent electroporation, INO-4800 carries the DNA plasmid directly into body cells. Inovio’s partner, Advaccine
This approval expands the total count of Covid-19 vaccines authorised in the country to five. Last week, J&J submitted an application seeking Emergency Use Authorization (EUA) for its
This vaccine candidate is based on the company’s Fc fusion protein platform. It stimulates a Th1/Th2 mixed immune response against the receptor-binding domain (RBD) of the SARS-CoV-2 spike
BRII-196 and BRII-198 are non-competing monoclonal antibodies obtained from convalesced Covid-19 patients. These antibodies neutralise SARS-CoV-2. The trial is funded by the NIH unit National Institute of Allergy
German pharmaceutical firm Bayer has agreed to acquire Vividion Therapeutic to strengthen its drug discovery capabilities. Vividion Therapeutics uses novel discovery technologies to develop therapies for patients with
The European Commission has finalised an advanced purchase agreement (APA) with Novavax to buy up to 200 million doses of NVX-CoV2373, the company’s Covid-19 vaccine candidate. NVX-CoV2373 is